518 related articles for article (PubMed ID: 10717776)
1. Effect of low-dose oral contraceptives on androgenic markers and acne.
Thorneycroft IH; Stanczyk FZ; Bradshaw KD; Ballagh SA; Nichols M; Weber ME
Contraception; 1999 Nov; 60(5):255-62. PubMed ID: 10717776
[TBL] [Abstract][Full Text] [Related]
2. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
Mango D; Ricci S; Manna P; Miggiano GA; Serra GB
Contraception; 1996 Mar; 53(3):163-70. PubMed ID: 8689881
[TBL] [Abstract][Full Text] [Related]
3. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial.
Moutos D; Smith S; Zacur H
Contraception; 1995 Aug; 52(2):105-9. PubMed ID: 8536446
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
Lemay A; Dewailly SD; Grenier R; Huard J
J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
[TBL] [Abstract][Full Text] [Related]
5. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
Wiegratz I; Jung-Hoffmann C; Kuhl H
Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
[TBL] [Abstract][Full Text] [Related]
6. Changes in androgens during treatment with four low-dose contraceptives.
Coenen CM; Thomas CM; Borm GF; Hollanders JM; Rolland R
Contraception; 1996 Mar; 53(3):171-6. PubMed ID: 8689882
[TBL] [Abstract][Full Text] [Related]
7. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
Kuhnz W; Staks T; Jütting G
Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
[TBL] [Abstract][Full Text] [Related]
9. Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction.
Sulak P; Lippman J; Siu C; Massaro J; Godwin A
Contraception; 1999 Mar; 59(3):161-6. PubMed ID: 10382078
[TBL] [Abstract][Full Text] [Related]
10. An open study of Triphasil and Diane 50 in the treatment of acne.
Wishart JM
Australas J Dermatol; 1991; 32(1):51-4. PubMed ID: 1834045
[TBL] [Abstract][Full Text] [Related]
11. Cycle control with oral contraceptives containing 20 micrograms of ethinyl estradiol. A multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 micrograms/20 micrograms) and norethindrone/ethinyl estradiol (1000 micrograms/20 micrograms).
DelConte A; Loffer F; Grubb GS
Contraception; 1999 Mar; 59(3):187-93. PubMed ID: 10382082
[TBL] [Abstract][Full Text] [Related]
12. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone.
Wild RA; Demers LM; Applebaum-Bowden D; Lenker R
Contraception; 1991 Aug; 44(2):113-24. PubMed ID: 1893706
[TBL] [Abstract][Full Text] [Related]
13. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives.
Anderson FD
Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552
[TBL] [Abstract][Full Text] [Related]
14. Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol.
Boyd RA; Zegarac EA; Posvar EL; Flack MR
Contraception; 2001 Feb; 63(2):71-6. PubMed ID: 11292470
[TBL] [Abstract][Full Text] [Related]
15. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
Godsland IF; Crook D; Devenport M; Wynn V
Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
[TBL] [Abstract][Full Text] [Related]
16. Changes in unbound sex steroids and sex hormone binding globulin--binding capacity during oral and vaginal progestogen administration.
Granger LR; Roy S; Mishell DR
Am J Obstet Gynecol; 1982 Nov; 144(5):578-84. PubMed ID: 6890312
[TBL] [Abstract][Full Text] [Related]
17. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
18. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Romus MA; Gillain D; Duvivier J; Demey-Ponsart E; Franchimont P
Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622
[TBL] [Abstract][Full Text] [Related]
19. A clinical comparison of two triphasic oral contraceptives with levonorgestrel or norethindrone: a prospective, randomized, single-blind study.
Masson S; Franssen E; Hilditch JR; Powell MG
Contraception; 1993 Jan; 47(1):43-54. PubMed ID: 8436001
[TBL] [Abstract][Full Text] [Related]
20. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]